|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||12.60 - 13.71|
|52 Week Range||6.80 - 17.98|
|Beta (3Y Monthly)||3.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.92|
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com.
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -45.83% and -7.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 35 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019
In a speech at the U.S. Department of Health and Human Services (HHS) on Oct. 25, President Trump detailed how he intends to reduce pharmaceutical prices. Because pharmacy drugs are exempt from the plan at this stage, the impact on pharmaceutical companies is likely to be minimal. However, investors should keep up to date with further developments relating to the Trump administration's blueprint to lower drug prices, which was released in May.
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The webcast will also be archived on the Company's website.
Eli Lilly And Co (NYSE: LLY) announced Monday it entered into a licensing and research collaboration with Dicerna, under which both companies will focus on discovery, development and commercialization drugs for cardio-metabolic diseases as well as for neurodegeneration and pain using the latter's GalXC RNAi technology platform. For licensing its platform, Dicerna stands to receive an upfront payment of $100 million as well as an equity investment of $100 million at a premium.
Shares of Dicerna Pharmaceuticals Inc. rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & Co. , to develop new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. Eli Lilly's stock was still inactive ahead of the open. Under terms of the deal, Eli Lilly has also made an equity investment of $100 million at a premium, and Dicerna will be eligible to receive up to $350 million per target in development and commercialization milestones. ""We are excited to collaborate with Dicerna and utilize their RNAi expertise to study targets that up until now have proven to be very technically challenging," said Eli Lilly Chief Scientific Officer Daniel Skovronsky. Dicerna shares have rallied 44% year to date through Friday, while Lilly's stock has climbed 26% and the S&P 500 has slipped 0.6%.
INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Dicerna Pharmaceuticals (DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.
The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront.
Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology. The companies expect to collaborate on developing more than 10 experimental drugs to treat pain, neuro-degenerative diseases and cardio-metabolic disorders. For the use of Dicerna's GalXC gene-silencing platform, Lilly will pay the company $100 million upfront and buy a $100 million equity stake at a per share price of $18.47, a 42 percent premium to Dicerna's close on Friday, Dicerna told Reuters.
Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of late-breaking data from its ongoing PHYOX Phase 1 trial, in which single-dose administration of DCR-PHXC, the Company’s lead GalXC™ product candidate, was associated with normalization or near-normalization of urinary oxalate levels in a majority of adult patients with primary hyperoxaluria types 1 and 2 (PH1 and PH2). In a poster presented at the American Society of Nephrology (ASN) Annual Kidney Week 2018 in San Diego, Calif., investigators reported that a single 3.0-mg/kg dose of DCR-PHXC brought urinary oxalate levels into the normal range (defined as 24-hour excretion ≤0.46 mmol) at one or more post-dose time points in three of four participants, including a mean maximal reduction in 24-hour urinary oxalate of 65%.
Alexion posted an "impressive" 54% operating margin in the third quarter, leading to a big beat on adjusted earnings, but shares slid Wednesday as revenue missed some estimates.
Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.
Alexion Pharmaceuticals Inc. shares surged 3% in Wednesday premarket trade after the company reported third-quarter profit and revenue beats and upbeat 2018 guidance. Earnings for the latest quarter rose to $330.9 million, or $1.47 per share, from $78 million, or 35 cents per share in the year-earlier period. Adjusted earnings-per-share were $2.02, compared with the FactSet consensus of $1.74. Revenue rose to $1.03 billion from $859 million, above the FactSet consensus of $1.02 billion. The latest results include major sales increases for the company's Soliris, Strensiq and Kanuma medications. Soliris and Kanuma sales beat the FactSet consensus, while Strensiq sales missed. Alexion now expects 2018 revenue of $4.02 billion to $4.05 billion, an increase from previous guidance of $3.98 billion to $4.01 billion, and 2018 adjusted EPS of $7.45 to $7.60, an increase from prior guidance of $7.00 to $7.15. Alexion also announced a collaboration with Dicerna Pharmaceuticals Inc. to develop a category of promising medications called RNA interference therapies. Dicerna will receive an upfront payment of $22 million and a $15 million equity investment from Alexion, and will be eligible for various milestone payments and royalties. Alexion shares have dropped 9.1% over the last three months, compared with a 2.8% decline in the S&P 500 and a 0.2% decline in the Dow Jones Industrial Average .
- Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary hyperoxaluria will be presented at the American Society of Nephrology Annual Kidney Week 2018, being held October 23-28 in San Diego.
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in October.
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?